Compositions and methods for correction of heritable ocular disease

Patent metadata

Field	Value
Publication number	US-10987433-B2
Application number	US-201615776663-A
Country	US
Kind code	B2
Filing date	Nov 18, 2016
Priority date	Nov 19, 2015
Publication date	Apr 27, 2021
Grant date	Apr 27, 2021

Abstract

A nucleic acid trans-splicing molecule is provided that can replace an exon in a targeted mammalian ocular gene carrying a defect or mutation causing an ocular disease with an exon having the naturally-occurring sequence without the defect or mutation. A method of treating an ocular disease, e.g., Stargardt's Disease, caused by a defect or mutation in a target gene, e.g., ABCA4 comprising: administering to the ocular cells of a subject having an ocular disease a composition comprising a recombinant AAV comprising a nucleic acid trans-splicing molecule as described above.

First claim

The invention claimed is:

1. A nucleic acid trans-splicing molecule comprising
(a) a binding domain (BD) that binds a target intron of a mammalian ABCA4 pre-mRNA carrying a defect or mutation causing an ocular disease,
(b) a splice site, and
(c) an exon sequence that encodes one more exons of an ABCA4 gene without the defect or mutation.

2. The molecule according to claim 1 , wherein the exon sequence comprises exons 1-22.

3. The molecule according to claim 1 , wherein the exon sequence comprises exons 27-50.

4. The molecule according to claim 1 , comprising:
(a) a BD that binds a target intron of an ABCA4 pre-mRNA 5′ to the defect or mutation in the ABCA4 pre-mRNA;
(b) an optional spacer;
(c) a 3′ splice site, and
(d) an exon sequence that encodes one or all exons of the mammalian ABCA4 gene that are 3′ to the target intron.

5. The molecule according to claim 4 , further comprising:
(e) a second BD that binds a target the ABCA4 pre-mRNA to the defect or mutation; and
(f) a 5′ splice site.

6. The molecule according to claim 4 , wherein the BD binds to a portion of intron 26 and the coding sequence encodes exons 27-50 of the ABCA4 gene.

7. The molecule according to claim 1 , comprising in sequential order:
(a) a BD that binds a target pre-mRNA of the ABCA4 gene 3′ to the defect or mutation in the ABCA4 pre-mRNA;
(b) a 5′ splice site;
(c) an optional spacer; and
(d) a sequence that encodes all exons of the ABCA4 gene that are 5′ to the target pre-mRNA intron.

8. The molecule according to claim 7 , wherein the BD binds to a portion of intron 22 and the coding sequence encodes exons 1-22 of the ABCA4 gene.

9. The molecule according to claim 1 , which is a nucleic acid sequence of up to 3000 bp in length.

10. A proviral plasmid comprising a wildtype 5′ AAV ITR sequence, a promoter comprising an ocular cell-specific promoter/enhancer, a multi-cloning polylinker sequence having inserted therein a nucleic acid sequence of the molecule of claim 1 , operatively linked to, and under the regulatory control of, the promoter; and a wildtype 3′ AAV ITR sequence.

11. The plasmid according to claim 10 , which is p618 comprising the nucleic acid sequence.

12. A recombinant adeno-associated virus comprising a nucleic acid trans-splicing molecule of claim 1 .

13. A method of treating an ocular disease caused by a defect or mutation in a mammalian ABCA4 gene comprising: administering to the ocular cells of a subject having an ocular disease a composition comprising the nucleic acid trans-splicing molecule of claim 1 .

14. The method according to claim 13 , wherein the disease is Stargardt Disease, cone rod dystrophy, fundus flavimaculatus, retinitis pigmentosa, or age-related macular degeneration.

15. The method according to claim 14 , wherein the disease is Stargardt Disease, the cells are photoreceptor cells, and the corrected exon sequence is Exons 1-22 or Exons 27-50.

16. The method according to claim 13 comprising administering a 5′ nucleic acid trans-splicing molecule or administering a 3′ nucleic acid trans-splicing molecule or administering a double nucleic acid trans-splicing molecule.

17. The method according to claim 13 , wherein the composition is administered by subretinal injection.

Assignees

• Univ Pennsylvania
• Mitchell Lloyd G

Inventors

• Bennett Jean
• Bennicelli Jeannette
• Dooley Scott J
• Mitchell Lloyd G

Classifications

• C12N2740/10043

  viral genome or elements thereof as genetic vector · CPC title

• C12N15/00

  Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered microorganisms, per se C12N1/00, C12N5/00, C12N7/00; new plants per se A01H; plant reproduction by tissue culture techniques A01H4/00; new animals per se A01K67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K48/00) · CPC title

• C12N2750/14143

  viral genome or elements thereof as genetic vector · CPC title

• C12N15/86

  Viral vectors · CPC title

• A61K48/005 Primary

  characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered · CPC title